Association of SLC13A2 rs11567842 genotypes with kidney function in calcium-oxalate stone disease: a feasibility study in a Ukrainian cohort.
5 affiliations
- 1O.O. Shalimov National Scientific Center of Surgery and Transplantology of the National Academy of Medical Science of Ukraine, 30 Heroes of Sevastopol Str., Kiev, 03680, Ukraine. [email protected].
- 2Taras Shevchenko National University of Kyiv, 60 Volodymyrka Str., Kiev, 01601, Ukraine. [email protected].
- 3Taras Shevchenko National University of Kyiv, 60 Volodymyrka Str., Kiev, 01601, Ukraine.
- 4National Scientific Center Named After M.D. Strazhesko NAMS of Ukraine, Kiev, Ukraine.
- 5Shupyk National Healthcare University of Ukraine, 9 Dorohozhytska Str., Kiev, 04112, Ukraine.
Abstract
Background
Calcium-oxalate (CaOx) nephrolithiasis is a common form of kidney stone disease (KSD) with potential progression to chronic kidney disease (CKD). Genetic factors, including variants in the SLC13A2 gene encoding the NaDC-1 citrate transporter, may modulate individual susceptibility. This pilot cross-sectional study evaluated the feasibility of implementing standardized genotyping and phenotype assessment workflows in CaOx nephrolithiasis patients to explore genotype-kidney function associations.Methods
Eighty adult patients with radiologically confirmed CaOx KSD were recruited from a tertiary care center in Kyiv, Ukraine (2024). Exclusion criteria included primary hyperoxaluria, secondary stone disease, and glomerular pathology. Genotyping for the SLC13A2 rs11567842 variant in peripheral blood DNA was performed using polymerase chain reaction followed by restriction fragment length analysis. Clinical and laboratory data were collected, including plasma oxalate concentration and estimated glomerular filtration rate (eGFR). Statistical analyses, including chi-square tests, Mann-Whitney tests, Kruskal-Wallis tests, and exploratory logistic regression (univariate and multivariable), were performed to evaluate the association between SLC13A2 rs11567842 genotypes and reduced kidney function (eGFR < 60 mL/min/1.73 m²).Results
Of the cohort (62.5% male, mean age [SD] 54.2 [16.2] years), 43.7% had eGFR < 60 mL/min/1.73 m². SLC13A2 rs11567842 genotype frequencies were AA 45.0%, AG 43.7%, and GG 11.3%. The GG genotype predominated in the eGFR < 60 group (p = 0.006, χ2 test). In an exploratory multivariable logistic regression analysis, the GG genotype was associated with reduced kidney function (OR = 7.8, 95% CI 1.6-16.4, p = 0.01), alongside age, hypertension, and diabetes.Conclusions
This pilot study demonstrated the feasibility of conducting integrated genetic and clinical phenotyping in CaOx KSD patients in a Ukrainian setting. Preliminary findings suggest a potential association between SLC13A2 rs11567842 and reduced kidney function, supporting the rationale for larger, longitudinal studies. Future research should incorporate urinary citrate/oxalate data and expanded genetic panels.
Related
- Genotypes and Longitudinal Change in the Cardiac Function in Patients with Suspected Idiopathic Cardiomyopathy
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del -gating and F508del -residual function genotypes: results from an open-label extension study
- Association of daily perceived stress with fertility outcomes in natural and controlled ovarian stimulation cycles: a feasibility study
- Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial
- Feasibility and effects of a multicomponent program incorporating esports on physical and cognitive function among older adults: A non-randomised pilot trial
BibTeX
@article{stepanova2026association,
title = {{Association of SLC13A2 rs11567842 genotypes with kidney function in calcium-oxalate stone disease: a feasibility study in a Ukrainian cohort.}},
author = {Natalia Stepanova and Liliia Fishchuk and Yaroslav Dubovyi and Nataliia Gorovenko and Andriy Sahalevych and Taisa Dovbynchuk and Ganna Tolstanova},
journal = {Pilot and feasibility studies},
year = {2026},
month = aug,
doi = {10.1186/s40814-026-01891-x},
url = {https://europepmc.org/article/MED/42958442},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Association of SLC13A2 rs11567842 genotypes with kidney function in calcium-oxalate stone disease: a feasibility study in a Ukrainian cohort.
AU - Natalia Stepanova
AU - Liliia Fishchuk
AU - Yaroslav Dubovyi
AU - Nataliia Gorovenko
AU - Andriy Sahalevych
AU - Taisa Dovbynchuk
AU - Ganna Tolstanova
PY - 2026
DA - 2026/08/01
JO - Pilot and feasibility studies
DO - 10.1186/s40814-026-01891-x
UR - https://europepmc.org/article/MED/42958442
AB - Background Calcium-oxalate (CaOx) nephrolithiasis is a common form of kidney stone disease (KSD) with potential progression to chronic kidney disease (CKD). Genetic factors, including variants in the SLC13A2 gene encoding the NaDC-1 citrate transporter, may modulate individual susceptibility. This pilot cross-sectional study evaluated the feasibility of implementing standardized genotyping and phenotype assessment workflows in CaOx nephrolithiasis patients to explore genotype-kidney function associations.Methods Eighty adult patients with radiologically confirmed CaOx KSD were recruited from a tertiary care center in Kyiv, Ukraine (2024). Exclusion criteria included primary hyperoxaluria, secondary stone disease, and glomerular pathology. Genotyping for the SLC13A2 rs11567842 variant in peripheral blood DNA was performed using polymerase chain reaction followed by restriction fragment length analysis. Clinical and laboratory data were collected, including plasma oxalate concentration and estimated glomerular filtration rate (eGFR). Statistical analyses, including chi-square tests, Mann-Whitney tests, Kruskal-Wallis tests, and exploratory logistic regression (univariate and multivariable), were performed to evaluate the association between SLC13A2 rs11567842 genotypes and reduced kidney function (eGFR < 60 mL/min/1.73 m²).Results Of the cohort (62.5% male, mean age [SD] 54.2 [16.2] years), 43.7% had eGFR < 60 mL/min/1.73 m². SLC13A2 rs11567842 genotype frequencies were AA 45.0%, AG 43.7%, and GG 11.3%. The GG genotype predominated in the eGFR < 60 group (p = 0.006, χ2 test). In an exploratory multivariable logistic regression analysis, the GG genotype was associated with reduced kidney function (OR = 7.8, 95% CI 1.6-16.4, p = 0.01), alongside age, hypertension, and diabetes.Conclusions This pilot study demonstrated the feasibility of conducting integrated genetic and clinical phenotyping in CaOx KSD patients in a Ukrainian setting. Preliminary findings suggest a potential association between SLC13A2 rs11567842 and reduced kidney function, supporting the rationale for larger, longitudinal studies. Future research should incorporate urinary citrate/oxalate data and expanded genetic panels.
SN - 2055-5784
ER -